<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative</title>
				<funder>
					<orgName type="full">Abbott</orgName>
				</funder>
				<funder>
					<orgName type="full">Roche</orgName>
				</funder>
				<funder>
					<orgName type="full">MSD</orgName>
				</funder>
				<funder>
					<orgName type="full">Bristol-Myers Squibb</orgName>
				</funder>
				<funder>
					<orgName type="full">GlaxoSmithKline</orgName>
				</funder>
				<funder>
					<orgName type="full">Celgene</orgName>
				</funder>
				<funder>
					<orgName type="full">American College of Rheumatology</orgName>
				</funder>
				<funder>
					<orgName type="full">Mundipharma</orgName>
				</funder>
				<funder>
					<orgName type="full">Merck</orgName>
				</funder>
				<funder>
					<orgName type="full">Amgen</orgName>
				</funder>
				<funder>
					<orgName type="full">Roche/Genentech</orgName>
				</funder>
				<funder>
					<orgName type="full">Berlin-Chemie</orgName>
				</funder>
				<funder>
					<orgName type="full">Mesoblast</orgName>
				</funder>
				<funder>
					<orgName type="full">Novartis</orgName>
				</funder>
				<funder>
					<orgName type="full">Centocor/Janssen</orgName>
				</funder>
				<funder>
					<orgName type="full">Sanofi</orgName>
				</funder>
				<funder>
					<orgName type="full">AbbVie</orgName>
				</funder>
				<funder>
					<orgName type="full">Genentech</orgName>
				</funder>
				<funder>
					<orgName type="full">Pfizer</orgName>
				</funder>
				<funder>
					<orgName type="full">Medac</orgName>
				</funder>
				<funder>
					<orgName type="full">European League Against Rheumatism</orgName>
				</funder>
				<funder>
					<orgName type="full">Servier</orgName>
				</funder>
				<funder>
					<orgName type="full">Ardea</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2015-10">October 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Christian</forename><surname>Dejaco</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">PhD: Medical University Graz</orgName>
								<orgName type="institution">Christian Dejaco</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, DM</roleName><forename type="first">Yogesh</forename><forename type="middle">P</forename><surname>Singh</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MSc</roleName><forename type="first">Pablo</forename><surname>Perel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><surname>Hutchings</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">London School of Hygiene and Tropical Medicine, Epidemiology and Population Health Faculty</orgName>
								<orgName type="institution">Andrew Hutchings</orgName>
								<address>
									<settlement>London</settlement>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dario</forename><surname>Camellino</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">London School of Hygiene and Tropical Medicine</orgName>
								<orgName type="department" key="dep2">Department of Health Services Research and Policy</orgName>
								<orgName type="institution">Dario Camellino</orgName>
								<address>
									<settlement>London</settlement>
									<region>MD Marco Cimmino MD</region>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sarah</forename><surname>Mackie</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Division of Clinical Rheumatology</orgName>
								<orgName type="laboratory">Research Laboratory and Academic</orgName>
								<orgName type="institution">University of Genoa</orgName>
								<address>
									<settlement>Genoa</settlement>
									<country>Italy;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andy</forename><surname>Abril</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Artur</forename><surname>Bachta</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD:</roleName><forename type="first">Peter</forename><surname>Balint</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kevin</forename><surname>Barraclough</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">3rd Rheumatology Department</orgName>
								<orgName type="institution">National Institute of Rheumatology and Physiotherapy</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country>Hungary;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lina</forename><surname>Bianconi</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">FRCP</orgName>
								<orgName type="institution" key="instit1">Kevin Barraclough</orgName>
								<orgName type="institution" key="instit2">MRCGP: Hoyland House</orgName>
								<address>
									<settlement>Painswick</settlement>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Buttgereit</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Lina Bianconi</orgName>
								<address>
									<region>MD: Bibbiano</region>
									<country>Italy;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Steven</forename><surname>Carsons</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">MD: Charit e University Medicine</orgName>
								<orgName type="department" key="dep2">Department of Rheumatology</orgName>
								<orgName type="institution">Frank Buttgereit</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>Germany;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Ching</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>Cid</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marco</forename><surname>Cimmino</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">London School of Hygiene and Tropical Medicine</orgName>
								<orgName type="department" key="dep2">Department of Health Services Research and Policy</orgName>
								<orgName type="institution">Dario Camellino</orgName>
								<address>
									<settlement>London</settlement>
									<region>MD Marco Cimmino MD</region>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Diamantopoulos</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Systemic Autoimmune Diseases</orgName>
								<orgName type="institution">University of Barcelona Hospital Clinic</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country>Spain;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">William</forename><surname>Docken</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christina</forename><surname>Duftner</surname></persName>
						</author>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Billy</forename><surname>Fashanu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kate</forename><surname>Gilbert</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pamela</forename><surname>Hildreth</surname></persName>
						</author>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Jane</forename><surname>Hollywood</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Jayne</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Manuella</forename><surname>Lima</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">FRCP: University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ajesh</forename><surname>Maharaj</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution" key="instit1">Manuella Lima</orgName>
								<orgName type="institution" key="instit2">MD: Hospital Universit ario Pedro Ernesto</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<country>Brazil;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Mallen</surname></persName>
							<affiliation key="aff24">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution" key="instit1">Ajesh Maharaj</orgName>
								<orgName type="institution" key="instit2">MBBS</orgName>
								<orgName type="institution" key="instit3">University of Kwa Zulu Natal</orgName>
								<orgName type="institution" key="instit4">Prince Mshiyeni Memo- rial Hospital</orgName>
								<orgName type="institution" key="instit5">Nelson R. Mandela School of Medicine</orgName>
								<address>
									<settlement>Durban</settlement>
									<country>South Africa;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Victor</forename><surname>Martinez-Taboada</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Arthritis Research UK Primary Care Centre</orgName>
								<orgName type="institution">Keele University</orgName>
								<address>
									<settlement>Keele</settlement>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mehrdad</forename><surname>Maz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Steven</forename><surname>Merry</surname></persName>
							<affiliation key="aff29">
								<orgName type="department" key="dep1">Department of Medi- cine</orgName>
								<orgName type="department" key="dep2">Division of Allergy</orgName>
								<orgName type="department" key="dep3">Clinical Immunology, and Rheumatology</orgName>
								<orgName type="institution">University of Kansas Medical Center</orgName>
								<address>
									<settlement>Kansas City</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jean</forename><surname>Miller</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Shunsuke</forename><surname>Mori</surname></persName>
							<affiliation key="aff30">
								<orgName type="department">Department of Family Medicine</orgName>
								<orgName type="institution">Steven Merry</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>MD: Mayo Clinic Minnesota</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lorna</forename><surname>Neill</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Elisabeth</forename><surname>Nordborg</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jennifer</forename><surname>Nott</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hannah</forename><surname>Padbury</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Colin</forename><surname>Pease</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Division of Clinical Rheumatology</orgName>
								<orgName type="laboratory">Research Laboratory and Academic</orgName>
								<orgName type="institution">University of Genoa</orgName>
								<address>
									<settlement>Genoa</settlement>
									<country>Italy;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carlo</forename><surname>Salvarani</surname></persName>
							<affiliation key="aff33">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Sahlgren University Hospital</orgName>
								<address>
									<addrLine>G€ oteborg</addrLine>
									<country>Sweden;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Michael</forename><surname>Schirmer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Schmidt</surname></persName>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">MD: Azienda Ospedaliera</orgName>
								<orgName type="department" key="dep2">Depart- ment of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Division of Rheumatology</orgName>
								<orgName type="institution" key="instit1">Carlo Salvarani</orgName>
								<orgName type="institution" key="instit2">IRCCS di Reggio Emilia</orgName>
								<address>
									<settlement>Reggio Emilia</settlement>
									<country>Italy;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><surname>Spiera</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Tronnier</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alexandre</forename><surname>Wagner</surname></persName>
						</author>
						<author>
							<persName><roleName>CNS</roleName><forename type="first">Madeline</forename><surname>Whitlock</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><forename type="middle">L</forename><surname>Matteson</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>MD, FRCP</roleName><forename type="first">Bhaskar</forename><surname>Dasgupta</surname></persName>
							<email>bhaskar.dasgupta@southend.nhs.uk.</email>
						</author>
						<author>
							<persName><forename type="first">Internal</forename><surname>Medicine</surname></persName>
						</author>
						<author>
							<persName><roleName>Warsaw, Poland</roleName><surname>Rheumatology</surname></persName>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Depart- ment of Rheumatology</orgName>
								<orgName type="institution">Southend University Hospi- tal</orgName>
								<address>
									<settlement>Graz</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Southend University Hospital</orgName>
								<address>
									<settlement>Essex</settlement>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Department of Rheumatology</orgName>
								<address>
									<settlement>Essex</settlement>
									<country>UK;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Sarah Mackie</orgName>
								<orgName type="institution" key="instit2">BM BCh</orgName>
								<orgName type="institution" key="instit3">MRCP</orgName>
								<address>
									<addrLine>PhD, Colin Pease</addrLine>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">FRCP: University of Leeds</orgName>
								<orgName type="institution" key="instit2">NIHR Leeds Musculo- skeletal Biomedical Research Unit</orgName>
								<orgName type="institution" key="instit3">Leeds Institute of Rheumatic and Musculoskeletal Medicine</orgName>
								<address>
									<addrLine>7 Andy Abril</addrLine>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">MD: Mayo Clinic</orgName>
								<address>
									<addrLine>8 Artur Bachta</addrLine>
									<settlement>Jacksonville</settlement>
									<region>Florida MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Department</orgName>
								<orgName type="institution">PhD: Military Institute of Medicine</orgName>
								<address>
									<postCode>2569</postCode>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">MD: Stony Brook</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology, Allergy and Immunology</orgName>
								<orgName type="institution" key="instit1">Steven Carsons</orgName>
								<orgName type="institution" key="instit2">University School of Medicine</orgName>
								<orgName type="institution" key="instit3">Winthrop-University Hospital Campus</orgName>
								<address>
									<addrLine>Mine- ola 14 Daniel Ching MBChB</addrLine>
									<region>New York</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">FRCP</orgName>
								<orgName type="department" key="dep2">Department of Rheumatology</orgName>
								<orgName type="institution">FRACP: Timaru Hos- pital</orgName>
								<address>
									<addrLine>15 Maria Cid</addrLine>
									<settlement>Timaru</settlement>
									<region>New Zealand MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">PhD: Hospital</orgName>
								<orgName type="institution">Andreas Diamantopoulos</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department">Department of Rheuma- tology</orgName>
								<orgName type="institution">Southern Norway Trust</orgName>
								<address>
									<addrLine>17 William Docken</addrLine>
									<settlement>Kristiansand</settlement>
									<region>Norway</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">MD: Brigham and Women&apos;s Hospital</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="institution">Medical Uni- versity of Innsbruck</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="department">Department of Internal Medicine-Clinic VI</orgName>
								<orgName type="institution">Hannah Padbury: patient representatives from Poly- myalgia Rheumatica and Giant Cell Arteritis UK</orgName>
								<address>
									<addrLine>Inns- bruck 20 David Jayne</addrLine>
									<settlement>London</settlement>
									<region>MD</region>
									<country>Austria; UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="institution" key="instit1">Christian Mallen</orgName>
								<orgName type="institution" key="instit2">MRCGP</orgName>
								<address>
									<region>PhD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="institution">Victor Martinez-Taboada</orgName>
								<address>
									<addrLine>PhD: Universidad de Can- tabria</addrLine>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff28">
								<orgName type="department">Facultad de Medicina</orgName>
								<orgName type="institution" key="instit1">Hospital Universitario Marqu es de Valdecilla</orgName>
								<orgName type="institution" key="instit2">Servicio de Reumatolog ıa</orgName>
								<address>
									<addrLine>25 Mehrdad Maz</addrLine>
									<settlement>Santander</settlement>
									<region>MD</region>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff31">
								<orgName type="institution">Shunsuke Mori</orgName>
								<address>
									<region>MD PhD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff32">
								<orgName type="department">Department of Rheumatol- ogy</orgName>
								<orgName type="institution" key="instit1">NHO Kumamoto Saishunsou National Hospital</orgName>
								<orgName type="institution" key="instit2">Clinical Research Center for Rheumatic Diseases</orgName>
								<address>
									<addrLine>28 Elisabeth Nordborg</addrLine>
									<settlement>Kohshi</settlement>
									<region>Kumamoto MD</region>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff35">
								<orgName type="department">MD: Immanuel Krankenhaus Berlin and Medical Center for Rheumatology Berlin-Buch</orgName>
								<orgName type="institution">Wolfgang Schmidt</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>Germany; 31</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff36">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">honoraria from UCB Pharma</orgName>
								<address>
									<settlement>Pfizer</settlement>
									<region>Cellerix</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff37">
								<orgName type="institution">Southend University Hospital</orgName>
								<address>
									<addrLine>Prittlewell Chase Westcliff-on-Sea</addrLine>
									<postCode>SS0 0RY</postCode>
									<settlement>Essex</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">2015 Recommendations for the Management of Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-10">October 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">4E3758F727ED5D273FE5CEB52C36D18A</idno>
					<idno type="DOI">10.1002/art.39333</idno>
					<note type="submission">Submitted for publication February 20, 2015; accepted in revised form July 13, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1" ident="GROBID" when="2025-03-15T10:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients' and clinicians' values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow-up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying antirheumatic drugs (DMARDs), as well as the roles of nonsteroidal anti-rheumatic drugs and non-pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.</p><p>The American College of Rheumatology is an independent, professional, medical and scientific society which does not guarantee, warrant, or endorse any commercial product or service.</p><p>Robert Spiera, MD: Hospital for Special Surgery, Department of Medicine, New York, New York; 32 David Tronnier: patient representative from the Mayo Clinic, Rochester, Minnesota; 33 Alexandre Wagner, MD, PhD: Universidade Federal de São Paulo, Department of Internal Medicine, São Paulo, Brazil; 34 Eric L. Matteson, MD, MPH: Mayo Clinic College of Medicine, Department of Health Sciences Research, Division of Rheumatology, Rochester, Minnesota.</p><p>Drs. Matteson and Dasgupta contributed equally to this work. Dr. Dejaco has received consulting fees, speaking fees, and/ or honoraria from Bristol-Myers Squibb, Pfizer, AbbVie, MSD, Merck Serono, and Roche, and research funding from Pfizer and MSD. Dr. Mackie has received consulting fees, speaking fees, and/or honoraria from Pfizer, Napp Pharmaceuticals, and AstraZeneca. Dr. Bachta has received consulting fees, speaking fees, and/or honoraria from Medac, Abbott, ENEL-MED, Wyeth, and Lilly, and research funding from Wyeth and Lilly. Dr. Balint has received consulting fees, speaking fees, and/or honoraria from Pfizer, SonoSite, and Abbott, and research funding from Abbott and Bristol-Myers Squibb. Dr. Buttgereit has received consulting fees, speaking fees, and/or honoraria from Merck Serono, Horizon Pharma, and Mundipharma, and research funding from Merck Serono and Horizon Pharma. Dr. Carsons has received consulting fees, speaking fees, and/or honoraria from Centocor. Dr. Cid has received consulting fees, speaking fees, and/or honoraria from Centocor, Roche, and Bristol-Myers Squibb. Dr. Cimmino has received consulting fees, speaking fees, and/or honoraria from Roche, Bristol-Myers Squibb, and Menarini, and research funding from Roche. Dr. Duftner has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers Squibb, Pfizer, AbbVie, MSD, Merck Serono, and Roche. Dr. Jayne has received consulting fees, speaking fees, and/or honoraria from Roche/Genentech, and research funding from the company. Dr. Maharaj has received consulting fees, speaking fees, and/or honoraria from AstraZeneca and Pfizer. Dr. Martinez-Taboada has received consulting fees, speaking fees, and/or Introduction There are wide variations in the treatment of polymyalgia rheumatica (PMR) with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common <ref type="bibr" target="#b0">(1)</ref><ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref>. GC side effects are frequently observed, occurring in around 50% of patients, and present a further challenge <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b5">6)</ref>. Well considered, international recommendations can serve to standardize practice and improve patient care.</p><p>Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient decision-making.</p><p>Target population. The target population are patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b6">(7)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref>. Management of PMR with concomitant giant cell arteritis (GCA), rheumatoid arthritis (RA) or other conditions that present with PMR features or mimic PMR is not addressed by these recommendations.</p><p>Target users. The target users of these recommendations are primary, secondary and tertiary care physicians (that is, general practitioners [GPs], specialists in general [internal] medicine and rheumatologists).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>For a detailed description of methods, see online supplementary file S1, on the Arthritis &amp; Rheumatology web site at <ref type="url" target="http://onlinelibrary.wiley.com/doi/10.1002/">http://onlinelibrary.wiley.com/doi/10.1002/</ref> art.39333/abstract.</p><p>In brief, we used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework <ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref>. We formulated 12 PICO (problem/population, intervention, comparison, and outcome) questions on interventions and 10 questions on prognostic factors (see online supplementary box S1A and S1B [<ref type="url" target="http://onlinelibrary.wiley.com/">http://onlinelibrary.wiley.com/</ref> doi/10.1002/art.39333/abstract], or the accompanying paper by Dejaco et al <ref type="bibr" target="#b15">[16]</ref>). The systematic literature review (SLR) was conducted by two investigators (CDe and YPS) using Ovid MEDLINE, Embase, PubMed, CINAHL, Web of Science and the Cochrane Library databases (from January 1970 until April 2014), and applying the thesauri of PMR, text words, abbreviations and truncated text words. Outcome parameters used in the SLR may be found in supplementary box S2 (<ref type="url" target="http://onlinelibrary">http://onlinelibrary</ref>. wiley.com/doi/10.1002/art.39333/abstract). Quality appraisal of interventional and prognostic studies was performed using GRADE <ref type="bibr" target="#b16">(17,</ref><ref type="bibr" target="#b17">18)</ref> and the Quality in Prognostic Studies (QUIPS) tool <ref type="bibr" target="#b18">(19)</ref>, respectively. According to GRADE methodology, a guideline panel should consider the following aspects when formulating recommendations: 1) overall quality of evidence; 2) balance between desirable and undesirable effects; 3) patients' and clinicians' values and preferences; and 4) resource use. External evidence (from other American College of Rheumatology [ACR]/ European League Against Rheumatism [EULAR] recommendations; see online supplementary table <ref type="table">S1</ref> [<ref type="url" target="http://onlinelibrary.wiley.com/doi/10.1002/art.39333/abstract">http:// onlinelibrary.wiley.com/doi/10.1002/art.39333/abstract</ref>] for details) on safety aspects related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs), GCs and methotrexate (MTX) was taken into account as indirect evidence, in order to identify the optimal trade-off between the benefit and harm of interventions. Prognostic factors were used to build subgroups and to adapt the recommendations based on the presence or absence of unfavorable prognostic factors. Final recommendations were either "in favor" or "against" an intervention, and were graded as "conditional" or "strong." A strong recommendation in favor (against) was considered when the panel was certain that benefits did (did not) outweigh risks and burdens, the preferences/values of patients were met (not met) and resource use was reasonable (unreasonably high). If uncertainty existed, a conditional recommendation was made.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>The results of the SLR are reported in a separate manuscript <ref type="bibr" target="#b15">(16)</ref>. See online supplementary file S2 (on the Arthritis &amp; Rheumatology web site at <ref type="url" target="http://onlinelibrary">http://onlinelibrary</ref>. wiley.com/doi/10.1002/art.39333/abstract) for a summary of the SLR and external evidence considered by the guideline panel.</p><p>General aspects. These recommendations should be understood as clinical advice and do not dictate the care of a particular patient. The EULAR and ACR consider adherence to these recommendations to be voluntary, with the physician making the ultimate decision to apply them in light of each patient's individual circumstances.</p><p>Overarching principles for the management of PMR. The group agreed upon several principles deemed to be fundamental aspects of clinical care in PMR as detailed in Box 1. These principles have not directly resulted from the SLR, but are consensus based. They are intended as a framework for the implementation of Box 1. Summary of the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR) Target population: Patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b6">(7)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref>.</p><p>Overarching principles for the management of PMR: A. Adoption of a safe and specific approach to ascertain the PMR case definition. The clinical evaluation should be directed toward exclusion of relevant mimicking (eg, non-inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, infective and neoplastic) conditions. B. Every case of PMR should have the following assessments prior to the prescription of therapy (primary or secondary care):</p><p>" Documentation of a basic laboratory dataset. This will help to exclude mimicking conditions and establish a baseline for monitoring of therapy. This should include rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies (ACPA), C-reactive protein and/or erythrocyte sedimentation rate (ESR), blood count, glucose, creatinine, liver function tests, bone profile (including calcium, alkaline phosphatase) and dipstick urinalysis. Additional investigations to consider are protein electrophoresis, thyroid stimulating hormone (TSH), creatine kinase and vitamin D. " Depending on clinical signs and symptoms and the likelihood of the alternative diagnoses, additional more extensive serological tests such as anti-nuclear antibodies (ANA), anti-cytoplasmic neutrophil antibodies (ANCA) or tuberculosis tests may be performed to exclude mimicking conditions. Additional investigations such as chest radiographs may be considered at the discretion of the physician in order to exclude other diagnoses. " Determination of comorbidities (particularly hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis [and particularly recent fractures]), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) as outlined in Smolen et al <ref type="bibr" target="#b20">(21)</ref> and Gossec et al <ref type="bibr" target="#b21">(22)</ref>, other relevant medications and risk factors for steroid-related side effects. Female sex was associated with a higher risk of glucocorticoid (GC) side effects in low to moderate quality studies <ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref>. " The role of risk factors for relapse/prolonged therapy is not clear yet. Baseline factors that were associated in low to moderate quality studies with a higher relapse rate and/or prolonged therapy in PMR studies were: female sex <ref type="bibr" target="#b23">(24,</ref><ref type="bibr" target="#b25">26)</ref>, high ESR (.40 mm/hour) <ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b30">(31)</ref> and peripheral inflammatory arthritis <ref type="bibr" target="#b31">(32)</ref>. A number of equally low to moderate quality studies, however, failed to demonstrate an association between these factors and relapse/prolonged therapy <ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b31">(32)</ref><ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref><ref type="bibr" target="#b35">(36)</ref><ref type="bibr" target="#b36">(37)</ref><ref type="bibr" target="#b37">(38)</ref><ref type="bibr" target="#b38">(39)</ref><ref type="bibr" target="#b39">(40)</ref><ref type="bibr" target="#b40">(41)</ref><ref type="bibr" target="#b41">(42)</ref><ref type="bibr" target="#b42">(43)</ref><ref type="bibr" target="#b43">(44)</ref>. C. Consideration of specialist referral, particularly in case of atypical presentation (such as peripheral inflammatory arthritis, systemic symptoms, low inflammatory markers, age ,60 years), experience of or high risk of therapy-related side effects, PMR refractory to GC therapy, and/or relapses/prolonged therapy. D. Treatment of PMR patients should aim at the best care and must be based on a shared decision between the patient and the treating physician. E. Patients should have an individualized PMR management plan. Patient perspective and preferences should be considered in the individualized choice of initial GC dose and subsequent tapering of GCs in PMR. F. Patients should have access to education focusing on the impact of PMR and treatment (including comorbidities and disease predictors) and advice on individually tailored exercise programs. G. Every patient treated for PMR in primary or secondary care should be monitored with the following assessments: risk factors and evidence for steroidrelated side effects, comorbidities, other relevant medications, evidence and risk factors for relapse/prolonged therapy. Continuous documentation of a minimal clinical and laboratory dataset should be conducted while prescribing GCs. Follow-up visits are suggested every 4-8 weeks in the first year, every 8-12 weeks in the second year, and as indicated in case of relapse or as prednisone is tapered and discontinued. H. It is important for patients to have rapid and direct access to advice from doctors, nurses or trained allied healthcare staff to report any changes in their condition such as flares and adverse events. Specific recommendations for the management of PMR patients: 1. The panel strongly recommends using GC instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/ or analgesics in PMR patients with pain related to other conditions. No specific recommendation can be made for analgesics. 2. The panel strongly recommends using the minimum effective individualized duration of GC therapy in PMR patients. 3. The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis, glaucoma, etc.) and other risk factors for GC-related side effects, a lower dose may be preferred. The panel discourages conditionally the use of initial doses #7.5 mg/day and strongly recommends against the use of initial doses .30 mg/day. 4. The panel strongly recommends individualizing dose tapering schedules, predicated to regular monitoring of patient disease activity, laboratory markers and adverse events.The following principles of GC dose tapering are suggested: A. Initial tapering: Taper dose to an oral dose of 10 mg/day prednisone equivalent within 4-8 weeks. B. Relapse therapy: Increase oral prednisone to the pre-relapse dose and decrease it gradually (within 4-8 weeks) to the dose at which the relapse occurred. C. Tapering once remission is achieved (following initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules such as 10/7.5 mg alternate days, etc.) until discontinuation given that remission is maintained. 5. The panel conditionally recommends considering intramuscular (i.m.) methylprednisolone as an alternative to oral GCs. The choice between oral GCs and i.m. methylprednisolone remains at the discretion of the treating physician. In one clinical trial, a starting dose of 120 mg methylprednisolone i.m. injection every 3 weeks was applied (23). 6. The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily). 7. The panel conditionally recommends considering early introduction of methotrexate (MTX) in addition to GCs, particularly in patients at a high risk for relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be considered during follow-up of patients with a relapse, without significant response to GC or experiencing GC-related adverse events. MTX has been used at oral doses of 7.5-10 mg/week in clinical trials (24-27). 8. The panel strongly recommends against the use of TNFa blocking agents for treatment of PMR. 9. The panel conditionally recommends considering an individualized exercise program for PMR patients aimed at the maintenance of muscle mass and function, and reducing risk of falls especially in older persons on long-term GCs as well as in frail patients. 10.The panel strongly recommends against the use of the Chinese herbal preparations Yanghe and Biqi capsules in PMR patients.  <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b6">(7)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref>. The algorithm assumes the consideration of overarching principles emphasizing the importance of assessing comorbidities, other relevant medications and possible risk factors for steroid-related side effects and relapse/ prolonged therapy. In addition, patients diagnosed in primary care should be considered for specialist referral, particularly in case of atypical presentation (such as peripheral inflammatory arthritis, systemic symptoms, low inflammatory markers, age ,60 years), experience or high risk of therapyrelated side effects and/or relapse/prolonged therapy. A minimal clinical and laboratory dataset should be documented in each patient before prescribing therapy. 1 Examples for comorbidities associated with an increased risk of glucocorticoid (GC)-related side effects are (according to Duru et al <ref type="bibr" target="#b31">[32]</ref> and Hoes et al <ref type="bibr" target="#b34">[35]</ref>): hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis (and particularly recent fractures), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with NSAIDs. 2 A baseline factor that was associated with a higher risk of GC-related adverse events in PMR studies was: female sex (37-39). 3 The role of risk factors for relapse/ prolonged therapy is not yet clear. Baseline factors that were associated with a higher relapse rate and/or prolonged therapy in PMR studies were: female sex <ref type="bibr" target="#b37">(38,</ref><ref type="bibr" target="#b46">47)</ref>, high erythrocyte sedimentation rate (ESR) (.40 mm/hour) <ref type="bibr" target="#b46">(47)</ref><ref type="bibr" target="#b47">(48)</ref><ref type="bibr" target="#b48">(49)</ref><ref type="bibr" target="#b49">(50)</ref><ref type="bibr" target="#b50">(51)</ref><ref type="bibr" target="#b52">53)</ref> and peripheral inflammatory arthritis <ref type="bibr" target="#b53">(54)</ref>. A number of studies, however, failed to demonstrate association between these factors and relapse <ref type="bibr" target="#b47">(48)</ref><ref type="bibr" target="#b48">(49)</ref><ref type="bibr" target="#b49">(50)</ref><ref type="bibr" target="#b50">(51)</ref><ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b66">(67)</ref><ref type="bibr" target="#b67">(68)</ref><ref type="bibr" target="#b68">(69)</ref><ref type="bibr" target="#b69">(70)</ref><ref type="bibr" target="#b70">(71)</ref><ref type="bibr" target="#b71">(72)</ref><ref type="bibr" target="#b72">(73)</ref><ref type="bibr" target="#b73">(74)</ref><ref type="bibr" target="#b74">(75)</ref><ref type="bibr" target="#b75">(76)</ref><ref type="bibr" target="#b76">(77)</ref><ref type="bibr" target="#b77">(78)</ref>. 4 Use the minimum effective dose out of a range of 12.5-25 mg prednisone equivalent daily: a high risk of relapse/prolonged therapy favors a higher dose, while a high risk of side effects favors a lower dose. 5 ln one randomized controlled trial, 120 mg methylprednisolone intramuscular (i.m.) injection was used every 3 weeks as a starting dose <ref type="bibr" target="#b22">(23)</ref>. I.m. methylprednisolone may not be available in all countries and the possible long-term benefit in terms of efficacy and GC-sparing effects of this preparation is unknown. 6 Methotrexate (MTX) has been used at oral doses of 7.5-10 mg/week in clinical trials (24-27). 7 Clinical improvement should be noted after 2 weeks, and almost complete response can be expected after 4 weeks. The definition of response criteria was beyond the scope of this project; however, a definition of response was proposed in Dasgupta et al <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4)</ref>  8 For initial GC tapering, we recommend reducing the oral dose gradually to a dose of 10 mg/ day prednisone equivalent within 4-8 weeks; after relapse therapy the dose should be decreased gradually (within 4-8 weeks) to the dose at which the relapse occurred. For i.m. methylprednisolone, a dose of 120 mg every 3 weeks was used for the first 9 weeks in Dasgupta et al <ref type="bibr" target="#b22">(23)</ref>. No recommendation about dose adjustments of MTX can be made. 9 The definition of criteria for remission and relapse was beyond the scope of this project. Definitions of remission and relapse used in clinical studies are summarized in Dejaco et al <ref type="bibr" target="#b64">(65)</ref>. 10 Once remission is achieved (following initial and relapse therapies), taper oral prednisone by 1 mg/4 weeks (or similar, eg, 2.5 mg/10 weeks) until discontinuation given that remission is maintained. In case i.m. methylprednisolone is used, the following tapering regimen was previously applied (23): 100 mg methylprednisolone i.m. at week 12, then continuation of the injections at monthly intervals with the dose reduced by 20 mg every 12 weeks until week 48. Thereafter, the dose was reduced by 20 mg every 16 weeks until discontinuation. 11 The group suggests that PMR patients be followed up every 4-8 weeks in the first year, every 8-12 weeks in the second year and as indicated in case of relapse or as prednisone is tapered off. 12 No recommendation can be made for minimal/optimal duration of therapy. In case patients are treated with a combination of GCs plus MTX and GCs have been withdrawn already, discontinuation of MTX may be considered. 13 lnitial lack of response (eg, insufficient improvement of symptoms within 2 weeks): increase oral dose up to 25 mg prednisone equivalent. In case i.m. methylprednisolone is used, consider switching to oral GCs. Relapse therapy: increase dose to the previously effective (ie, pre-relapse) dose.</p><p>the specific treatment recommendations and are of a general "overarching" nature, a concept adapted from earlier EULAR recommendations <ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref>.</p><p>Specific recommendations. See Box 1 for a summary of the recommendations. A flow-chart for the management of PMR patients is depicted in Figure <ref type="figure" target="#fig_0">1</ref>.</p><p>Recommendation 1: (PICO 1) The panel strongly recommends using GCs instead of NSAIDs in patients with PMR, with the exception of possible short-term use of NSAIDs and/or analgesics in PMR patients with pain related to other conditions (eg, co-existing osteoarthritis). No specific recommendation can be made for analgesics.</p><p>Explanation: The group recommends strongly against the use of NSAIDs compared to GCs in the treatment of PMR since the relative harm of long-term NSAID use (as mainly indicated by external evidence) outweighs the possible small benefits in PMR. No specific recommendation can be made for analgesics. On a basis of consensus, the panel recognized that the short-term use of NSAIDs and/or analgesics may be necessary in the setting of pain related to conditions other than PMR.</p><p>Recommendation 2: (PICO 2) The panel strongly recommends using the minimum effective individualized duration of GC therapy in PMR patients.</p><p>A more specific recommendation is not possible due to the lack of published evidence on this issue. On a basis of consensus and in accordance with the overarching principles, the group unanimously agreed to choose the minimum effective individualized duration and dose of GCs to balance benefit versus harm after assessing risk factors for GC-related adverse events, comorbidities, concomitant medications, relapses and prolonged therapy. Our recommended GC tapering schedule (see Recommendation 4) assumes a minimum of 12 months of treatment. A more specific statement is not possible because of the lack of PMR studies on this particular topic and because of the multiple subgroups and factors that need to be taken into account.</p><p>Recommendation 3: (PICOs 3-5) The panel conditionally recommends using the minimum effective GC dose within a range of 12.5-25 mg prednisone equivalent daily as the initial treatment of PMR. A higher initial prednisone dose within this range may be considered in patients with a high risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis, glaucoma, etc.) and other risk factors for GC-related side effects, a lower dose may be preferred. The panel discourages conditionally the use of initial doses #7.5 mg/day and strongly recommends against the use of initial doses .30 mg/day.</p><p>According to the SLR on prognostic factors and based on clinical experience, the group agreed upon the existence of various PMR subgroups that are characterized by different risks of relapse, prolonged GC therapy and/or GC-related adverse events as well as by various comorbidities and co-medications. As there are insufficient data to make evidence-based recommendations for all conceivable subgroups, and taking current clinical practice into account <ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>, the panel agreed upon the use of the minimum effective GC dose out of a range of 12.5-25 mg prednisone equivalent daily balancing benefits versus harms. The panel did not construct case vignettes as a possible aid for clinical practice; however, it is suggested that a higher initial prednisone dose (within the given range) may be used in patients with a high risk of relapse and low risk of adverse events, whereas in patients with relevant comorbidities (eg, diabetes, osteoporosis, glaucoma, etc.) and other risk factors for GCrelated side effects, a lower dose may be preferred.</p><p>The group conditionally discourages low (#7.5 mg/ day) and strongly recommends against high (.30 mg/day prednisone equivalent) initial GC doses. For this statement the group extrapolated the data from randomized controlled trials <ref type="bibr" target="#b28">(29,</ref><ref type="bibr" target="#b30">31)</ref>, and took clinical experience, national PMR guidelines <ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>, as well as current ACR and/or EULAR recommendations on the use of GCs in rheumatic diseases into account <ref type="bibr" target="#b31">(32)</ref><ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref>. In addition, there is incontrovertible external evidence of harm from longterm large doses of GCs <ref type="bibr" target="#b31">(32)</ref><ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref> and lack of evidence for any benefit of a high-dose regimen in PMR. It was unanimously agreed among the group that patients requiring high doses of GCs should be evaluated for alternate diagnoses and an alternate management plan.</p><p>Recommendation 4: (PICO 6) The panel strongly recommends individualizing dose-tapering schedules, based on regular monitoring of patient disease activity, laboratory markers and adverse events.</p><p>The following principles of GC dose tapering are suggested:</p><p>A. Initial tapering: Taper dose to an oral dose of 10 mg/day prednisone equivalent within 4-8 weeks. B. Relapse therapy: Increase oral prednisone to the pre-relapse dose and decrease it gradually (within 4-8 weeks) to the dose at which the relapse occurred. C. Tapering once remission is achieved (following initial and relapse therapies): Taper daily oral prednisone by 1 mg every 4 weeks (or by 1.25 mg decrements using schedules such as 10/7.5 mg on alternate days, etc.) until discontinuation as long as remission is maintained.</p><p>In accordance with the overarching principles, the panel agreed upon a strong recommendation to 2574 DEJACO ET AL individualize dose tapering and to regularly monitor PMR patients. Further, the panel proposed general principles for initial and post-relapse tapering of GCs (based on consensus and current clinical practice) but did not fix a schedule as in other guidelines <ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>. The panel agreed that equivalent objectives may be achieved by alternative tapering schedules. For example, a patient with a high initial prednisone dose (eg, 25 mg/day) may have a fast initial taper followed by a more gradual decrease in the GC dose, whereas in a patient starting at a lower initial dose (eg, 12.5 mg/day), the initial dose may be kept constant for longer and then eventually reduced.</p><p>The group suggested prednisone should be tapered by 1 mg/4 weeks or similar once remission is achieved. Again, the panel emphasized the important overall principle of gradual GC reduction without the need to prescribe a fixed schedule. The group further recognized that 1 mg prednisone tablets are not available in all countries (making a reduction of 1 mg/4 weeks unfeasible) and that other regimens such as alternate day reductions (eg, 10/7.5 mg on alternate days, etc.) are common clinical practice <ref type="bibr" target="#b27">(28)</ref>.</p><p>Recommendation 5: (PICO 7) The panel conditionally recommends considering intramuscular (i.m.) methylprednisolone as an alternative to oral GCs. The choice between oral GCs and i.m. methylprednisolone remains at the discretion of the treating physician.</p><p>In one clinical trial, i.m. methylprednisolone was applied at a dose of 120 mg every 3 weeks until week 9. At week 12, 100 mg were used and subsequently, injections were continued at monthly intervals and the dose was reduced by 20 mg every 12 weeks until week 48. Thereafter, the dose was reduced by 20 mg every 16 weeks until discontinuation <ref type="bibr" target="#b22">(23,</ref><ref type="bibr" target="#b35">36)</ref>.</p><p>The panel did not specify a clinical phenotype where i.m. GCs would be appropriate or adequate therapy; however, the panel agreed that in clinical practice this preparation may be considered in cases where a lower cumulative GC dose is desirable, for example in female patients with difficult to control hypertension, diabetes, osteoporosis and/or glaucoma <ref type="bibr" target="#b36">(37)</ref><ref type="bibr" target="#b37">(38)</ref><ref type="bibr" target="#b38">(39)</ref>. Nonetheless, the panel acknowledged that there is a lack of convincing evidence showing significantly fewer side effects with i.m. methylprednisolone than with oral GC therapy.</p><p>The reasons why the panel did not endorse a strong recommendation for the use of i.m. methylprednisolone are the following: 1) the efficacy of i.m. methylprednisolone is supported by a single randomized controlled trial and confirmation of these data is still necessary <ref type="bibr" target="#b22">(23,</ref><ref type="bibr" target="#b35">36)</ref>; 2) this trial was neither designed nor powered as a non-inferiority trial and therefore, a differ-ence between the efficacy of i.m. and oral GC cannot be excluded; 3) the trial failed to demonstrate a reduction in GC-related adverse events except for weight gain; 4) the long-term benefit of this preparation is unknown (particularly with respect to a possible reduction in GC side effects); and 5) i.m. methylprednisolone is not available in all countries.</p><p>Recommendation 6: (PICO 8) The panel conditionally recommends using a single rather than divided daily doses of oral GCs for the treatment of PMR, except for special situations such as prominent night pain while tapering GCs below the low-dose range (prednisone or equivalent ,5 mg daily).</p><p>There are no studies available addressing this issue specifically in PMR. Based on clinical experience and because of the concern that adverse events (including disturbance of the hypothalamic-pituitary-adrenal axis) may be higher with divided doses, the group agreed against the general use of divided GC doses in PMR <ref type="bibr" target="#b39">(40)</ref><ref type="bibr" target="#b40">(41)</ref><ref type="bibr" target="#b41">(42)</ref><ref type="bibr" target="#b42">(43)</ref>. The effectiveness and acceptability of a single daily GC dose has been standard clinical practice in PMR and other inflammatory conditions <ref type="bibr" target="#b43">(44,</ref><ref type="bibr" target="#b44">45)</ref> and evening doses can cause circadian rhythm and sleep disturbances <ref type="bibr" target="#b45">(46)</ref>.</p><p>In special situations such as in case of night pain while tapering below the low-dose range (prednisone or equivalent ,5 mg daily), split doses may be considered. However, persistent breakthrough symptoms should prompt re-consideration of the diagnosis.</p><p>Recommendation 7: (PICO 9) The panel conditionally recommends considering early introduction of MTX in addition to GCs, particularly in patients at high risk of relapse and/or prolonged therapy as well as in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be considered during follow-up in patients with a relapse, without a significant response to GC or experiencing GC-related adverse events.</p><p>In clinical trials, MTX has been used at oral doses of 7.5-10 mg/week <ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref>.</p><p>Similar to the explanation of Recommendation 5, the panel felt that there is no clinical prototype unconditionally warranting treatment with MTX, rather the use of this drug should be discussed on an individual basis. In clinical practice, MTX may be considered for example in female patients <ref type="bibr" target="#b35">(36,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b46">47)</ref> with high initial erythrocyte sedimentation rate (ESR) (.40 mm/hour) <ref type="bibr" target="#b47">(48)</ref><ref type="bibr" target="#b48">(49)</ref><ref type="bibr" target="#b49">(50)</ref><ref type="bibr" target="#b50">(51)</ref><ref type="bibr" target="#b51">(52)</ref><ref type="bibr" target="#b52">(53)</ref>, peripheral inflammatory arthritis <ref type="bibr" target="#b53">(54)</ref> and/or comorbidities that may be exacerbated by GC therapy.</p><p>The panel also reached a consensus that MTX should be considered in patients who have relapsed (either on or off GCs), cases without significant response to GC or patients experiencing GC-related adverse events. The group further agreed that MTX may be used with oral or i.m. GC preparations even if the concomitant use of MTX and i.m. methylprednisolone has not been tested formally.</p><p>The efficacy of MTX was addressed in four randomized controlled trials and one retrospective study testing the use of MTX plus oral GCs (initial prednisone doses ranging from 15 to 25 mg/day) <ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b50">51)</ref>. There was moderate to high quality of evidence (QoE) from studies indicating a benefit of MTX regarding remission (1 study) <ref type="bibr" target="#b26">(27)</ref>, relapse rate (1 study) <ref type="bibr" target="#b23">(24)</ref>, discontinuation of GC (1 study) <ref type="bibr" target="#b23">(24)</ref> and cumulative GC doses (3 studies) <ref type="bibr" target="#b23">(24,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27)</ref>. Evidence from one to four studies (1 related to remission, 4 to relapse, 1 to discontinuation of GC) indicating no benefit regarding these outcomes was of very low quality <ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b50">51)</ref>.</p><p>The reasons why the panel did not support a stronger recommendation for the use of MTX in PMR are the following: 1) the total number of patients investigated in randomized trials was small (n5194) <ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref>, hence further confirmation of the present data is necessary; 2) results were contradictory in part, although trials with a negative result had a very low QoE; 3) a reduction in GC-related adverse events with the use of MTX has not been demonstrated. The power of the prospective studies to address this outcome, however, was insuffi-cient. The panel nevertheless felt that earlier discontinuation of GC <ref type="bibr" target="#b23">(24)</ref> and a lower cumulative GC dose in MTX users <ref type="bibr" target="#b25">(26,</ref><ref type="bibr" target="#b26">27)</ref> decreases the likelihood of GCrelated side effects; and 4) the cost-effectiveness of MTX use in PMR is not clear. More frequent prescriptions of MTX may lead to higher utilization of healthcare resources in the short term (eg, because of specialist referral, monitoring visits, blood tests, etc.) but may in the long term save costs by reducing GC-related side effects. Future studies are necessary to clarify this issue.</p><p>The group recognized that no recommendation can be made for the use of other non-biologic (ie, conventional synthetic and conventional targeted) DMARDs in PMR because of the lack of good evidence from PMR studies. Hydroxychloroquine was investigated by a single very low QoE retrospective study reporting no benefit regarding relapse rate <ref type="bibr" target="#b50">(51)</ref>.</p><p>Recommendation 8: (PICOs 10-11) The panel strongly recommends against the use of TNFa blocking agents for the treatment of PMR.</p><p>The group agreed strongly against the use of TNFa blocking agents in PMR at this time since there is no evidence for benefit, but there is a considerable risk of potential harm and high resource use <ref type="bibr" target="#b54">(55)</ref>.</p><p>No recommendation can be made for other biologic agents as no prospective trials have been published so far. There is one ongoing randomized study on the The group agreed that future studies in polymyalgia rheumatica (PMR) should be multicenter and properly powered using an agreed, validated core outcome set and a robust trial design that would maximize the power of studies, facilitate regulatory approvals and allow future meta-analysis. Specific research questions: 1. Which outcome measures including patient-related outcomes, and response, remission and relapse criteria should be used in PMR? What is the value of a composite score? What are the most relevant treatment targets in PMR? 2. What is the efficacy and safety of different routes of glucocorticoid (GC) administration (oral, intramuscular, intra-articular), different initial GC doses, various GC tapering regimens, and different GC flare doses? 3. What is the efficacy and safety of DMARDs (non-TNFa biologic, conventional synthetic and conventional targeted) in PMR? What is the optimal strategy for using DMARDs in PMR: monotherapy versus combination therapy, early versus late introduction, and (particularly for biologics) use with or without GCs? 4. What is the minimal/optimal duration of therapy and which strategies for withdrawing GCs and/or DMARDs yield the best efficacy/safety profile? 5. What is the optimal strategy for shared primary and specialty care including recommendations for specialist referral? How can patients be better involved in treatment decisions, and are there any decision aids? What is the role of self-management? 6. What is the value of tight control (ie, treat to target) versus conventional management strategies in PMR? 7. How should patients with long-standing disease and long-term low-dose GC therapy be managed? 8. What is the cost utility and effectiveness of DMARD use in PMR (versus GC use alone)? 9. What is the value of non-pharmacological therapies in PMR? Particularly, it is assumed but not yet demonstrated that physiotherapy may support preservation of function and reduce the risk of adverse events related to GC use. Patients may benefit from exercise by maintaining muscle mass and function as well as by fall prevention especially in the frail. What is the role of diet in PMR and nutrition supplements (eg, fish oil) related to outcomes? 10. What is the efficacy and safety of herbal preparations in PMR? 11. What is the role of imaging (particularly ultrasound) for the assessment and monitoring of PMR, identification of overlap with other diseases (eg, large vessel vasculitis or inflammatory arthritis) alongside clinical and patient reported outcomes? 12. Which biomarkers may be useful in PMR? Why do some patients do better than others? How can we identify these groups and what is the biological mechanism behind it? Should different drugs be applied to different PMR subgroups? 13. What is the morbidity and mortality of PMR patients (with a particular focus on cardiovascular risk) in long-term observational studies? There are no studies investigating the value of non-pharmacological therapies (eg, physiotherapy, relaxation techniques, diets, etc.) in PMR and there is insufficient clinical experience on this issue to agree on a specific recommendation. Nevertheless, the panel agreed on recommending an individualized exercise program (see overarching principles) in view of its benefit for maintaining muscle mass and function and reducing risk of falls, especially in older persons on long-term GCs as well as in frail patients.</p><p>Use of herbal preparations in PMR. The panel strongly recommends against the use of the Chinese herbal preparations Yanghe and Biqi capsules in PMR patients.</p><p>There were some discussions about whether herbal preparations could be considered non-pharmacological interventions (and were therefore within the scope of PICO 12); however, the panel felt the need for comment on this issue because several preparations are available which may be popular with PMR patients.</p><p>The SLR identified two studies testing Chinese Yanghe herb decoction and Chinese Biqi capsules in PMR patients <ref type="bibr" target="#b55">(56,</ref><ref type="bibr" target="#b56">57)</ref>. For Chinese Yanghe there is moderate QoE for a lower ESR at week 8 (mean difference 6.0 mm/hour) and 12 (6.4 mm/hour) and very low QoE indicating a lower rate of GC-related adverse events (with borderline significance of the effect estimate) as well as reduced morning stiffness at week 12 <ref type="bibr" target="#b55">(56)</ref>. For Biqi capsules there is low QoE indicating a higher response rate at week 12 <ref type="bibr" target="#b56">(57)</ref>.</p><p>The group nevertheless agreed (after balancing evidence, benefit/harm, availability and resource use) to recommend strongly against the regular use of these preparations at this time for the following reasons: 1) the relevance of the small effect of Chinese Yanghe herb decoction on ESR is minimal for patients and good evidence for a clinical benefit of the substance is not available; 2) neither of the two substances is approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA); 3) the generalizability of the evidence for benefit is unclear; 4) these preparations may have unforeseeable adverse effects; 5) the availability of high quality preparations is unclear; and 6) resource impact (ie, costs) is unknown.</p><p>Release and implementation of the recommendations. See online supplementary file S2, on the Arthritis &amp; Rheumatology web site at <ref type="url" target="http://onlinelibrary">http://onlinelibrary</ref>. wiley.com/doi/10.1002/art.39333/abstract.</p><p>Cost implications and conflicts of interest. Cost implications are outside the scope of these recommendations.</p><p>None of the panel members disclosed any conflict of interest associated with the development of these recommendations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>See online supplementary file S3 (<ref type="url" target="http://online">http://online</ref> library.wiley.com/doi/10.1002/art.39333/abstract) for a full-length discussion. The 2015 EULAR/ACR recommendations for the management of PMR is the first collaborative project between EULAR and ACR to endorse treatment recommendations in rheumatology.</p><p>We recognize that our recommendations are only partially supported by evidence, and that they do not cover all aspects important for the management of PMR. The group therefore unanimously agreed that the research agenda (containing the evidence gaps related to PMR management) is an important result of this project (Box 2).</p><p>Due to our rigorous SLR approach to select high quality papers, we did not include other reviews, case reports or case series indicating possible treatment options in treatment-resistant PMR patients. For example, we found one earlier SLR reporting similar conclusions regarding the value of MTX in PMR <ref type="bibr" target="#b57">(58)</ref>. In addition, two case series were recently published on the use of leflunomide <ref type="bibr" target="#b58">(59,</ref><ref type="bibr" target="#b59">60)</ref> and a few case reports are available on tocilizumab <ref type="bibr" target="#b60">(61)</ref><ref type="bibr" target="#b61">(62)</ref><ref type="bibr" target="#b62">(63)</ref>. Azathioprine has been tested in a doubleblind randomized controlled trial in patients with PMR and GCA; however, as PMR patients were not analyzed separately, we did not include this study in the SLR <ref type="bibr" target="#b63">(64)</ref>.</p><p>It was beyond the scope of this recommendation project to define treatment targets in PMR. "Clinical improvement" was considered as the first treatment goal after the initiation of GCs, and the response criteria used in the 2012 classification criteria study may be considered <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4)</ref>. Remission and relapse have been heterogeneously defined in the literature, as we pointed out previously <ref type="bibr" target="#b64">(65)</ref>. Future prospective studies aimed at the validation of new definitions of response, remission and relapse are, therefore, required to enable a targeted treatment approach in PMR <ref type="bibr" target="#b65">(66)</ref>.</p><p>The most important limitations of this project are the paucity of high quality trials (as mentioned above) and the fact that GRADE is less well developed for the assessment of rare outcomes. Consequently, the QoE for</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Figure1. Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia rheumatica (PMR). The algorithm is applied to patients with PMR based on clinician diagnosis which may be supported by currently available diagnostic or classification criteria<ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b6">(7)</ref><ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref>. The algorithm assumes the consideration of overarching principles emphasizing the importance of assessing comorbidities, other relevant medications and possible risk factors for steroid-related side effects and relapse/ prolonged therapy. In addition, patients diagnosed in primary care should be considered for specialist referral, particularly in case of atypical presentation (such as peripheral inflammatory arthritis, systemic symptoms, low inflammatory markers, age ,60 years), experience or high risk of therapyrelated side effects and/or relapse/prolonged therapy. A minimal clinical and laboratory dataset should be documented in each patient before prescribing therapy.1 Examples for comorbidities associated with an increased risk of glucocorticoid (GC)-related side effects are (according to Duru et al<ref type="bibr" target="#b31">[32]</ref> and Hoes et al<ref type="bibr" target="#b34">[35]</ref>): hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis (and particularly recent fractures), presence of cataract or (risk factors for) glaucoma, presence of chronic or recurrent infections, and co-medication with NSAIDs.2 A baseline factor that was associated with a higher risk of GC-related adverse events in PMR studies was: female sex (37-39).3 The role of risk factors for relapse/ prolonged therapy is not yet clear. Baseline factors that were associated with a higher relapse rate and/or prolonged therapy in PMR studies were: female sex<ref type="bibr" target="#b37">(38,</ref><ref type="bibr" target="#b46">47)</ref>, high erythrocyte sedimentation rate (ESR) (.40 mm/hour)<ref type="bibr" target="#b46">(47)</ref><ref type="bibr" target="#b47">(48)</ref><ref type="bibr" target="#b48">(49)</ref><ref type="bibr" target="#b49">(50)</ref><ref type="bibr" target="#b50">(51)</ref><ref type="bibr" target="#b52">53)</ref> and peripheral inflammatory arthritis<ref type="bibr" target="#b53">(54)</ref>. A number of studies, however, failed to demonstrate association between these factors and relapse<ref type="bibr" target="#b47">(48)</ref><ref type="bibr" target="#b48">(49)</ref><ref type="bibr" target="#b49">(50)</ref><ref type="bibr" target="#b50">(51)</ref><ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b66">(67)</ref><ref type="bibr" target="#b67">(68)</ref><ref type="bibr" target="#b68">(69)</ref><ref type="bibr" target="#b69">(70)</ref><ref type="bibr" target="#b70">(71)</ref><ref type="bibr" target="#b71">(72)</ref><ref type="bibr" target="#b72">(73)</ref><ref type="bibr" target="#b73">(74)</ref><ref type="bibr" target="#b74">(75)</ref><ref type="bibr" target="#b75">(76)</ref><ref type="bibr" target="#b76">(77)</ref><ref type="bibr" target="#b77">(78)</ref>.4 Use the minimum effective dose out of a range of 12.5-25 mg prednisone equivalent daily: a high risk of relapse/prolonged therapy favors a higher dose, while a high risk of side effects favors a lower dose.5 ln one randomized controlled trial, 120 mg methylprednisolone intramuscular (i.m.) injection was used every 3 weeks as a starting dose<ref type="bibr" target="#b22">(23)</ref>. I.m. methylprednisolone may not be available in all countries and the possible long-term benefit in terms of efficacy and GC-sparing effects of this preparation is unknown.6 Methotrexate (MTX) has been used at oral doses of 7.5-10 mg/week in clinical trials (24-27).7 Clinical improvement should be noted after 2 weeks, and almost complete response can be expected after 4 weeks. The definition of response criteria was beyond the scope of this project; however, a definition of response was proposed in Dasgupta et al<ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b3">4)</ref> 8 For initial GC tapering, we recommend reducing the oral dose gradually to a dose of 10 mg/ day prednisone equivalent within 4-8 weeks; after relapse therapy the dose should be decreased gradually (within 4-8 weeks) to the dose at which the relapse occurred. For i.m. methylprednisolone, a dose of 120 mg every 3 weeks was used for the first 9 weeks in Dasgupta et al<ref type="bibr" target="#b22">(23)</ref>. No recommendation about dose adjustments of MTX can be made.9 The definition of criteria for remission and relapse was beyond the scope of this project. Definitions of remission and relapse used in clinical studies are summarized in Dejaco et al<ref type="bibr" target="#b64">(65)</ref>.10 Once remission is achieved (following initial and relapse therapies), taper oral prednisone by 1 mg/4 weeks (or similar, eg, 2.5 mg/10 weeks) until discontinuation given that remission is maintained. In case i.m. methylprednisolone is used, the following tapering regimen was previously applied (23): 100 mg methylprednisolone i.m. at week 12, then continuation of the injections at monthly intervals with the dose reduced by 20 mg every 12 weeks until week 48. Thereafter, the dose was reduced by 20 mg every 16 weeks until discontinuation.11 The group suggests that PMR patients be followed up every 4-8 weeks in the first year, every 8-12 weeks in the second year and as indicated in case of relapse or as prednisone is tapered off.12 No recommendation can be made for minimal/optimal duration of therapy. In case patients are treated with a combination of GCs plus MTX and GCs have been withdrawn already, discontinuation of MTX may be considered.13 lnitial lack of response (eg, insufficient improvement of symptoms within 2 weeks): increase oral dose up to 25 mg prednisone equivalent. In case i.m. methylprednisolone is used, consider switching to oral GCs. Relapse therapy: increase dose to the previously effective (ie, pre-relapse) dose.</figDesc><graphic coords="5,90.35,99.68,431.65,292.45" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Box 2 .</head><label>2</label><figDesc>Research agenda</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>14 .</head><label>14</label><figDesc>What is the etiopathogenesis of PMR? Which targeted therapies could be developed based on new knowledge of disease mechanisms? Bolded points indicate the top 5 items of the research agenda according to the opinion of the guideline panel. 2576 DEJACO ET AL use of tocilizumab (clinicaltrials.gov NCT01396317) and another three-arm trial comparing secukinumab, canakinumab and GCs (clinicaltrials.gov NCT01364389) in PMR. The results of these studies may lead to a modification of this recommendation. Recommendation 9: (PICO 12) The panel conditionally recommends considering an individualized exercise program for PMR patients aimed at the maintenance of muscle mass and function, and reducing risk of falls.</figDesc></figure>
		</body>
		<back>

			<div type="funding">
<div><p>Supported by research grants from the <rs type="funder">American College of Rheumatology</rs> and the <rs type="funder">European League Against Rheumatism</rs>. and <rs type="funder">Abbott</rs>, and research funding from <rs type="funder">Roche</rs>. <rs type="person">Dr. Mori</rs> has received research funding from <rs type="funder">Bristol-Myers Squibb</rs>. <rs type="person">Dr. Salvarani</rs> has received consulting fees, speaking fees, and/or honoraria from <rs type="funder">Novartis</rs>. <rs type="person">Dr. Schirmer</rs> has received consulting fees, speaking fees, and/or honoraria from <rs type="funder">Abbott</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">Amgen</rs>, <rs type="funder">GlaxoSmithKline</rs>, and <rs type="funder">MSD</rs>. <rs type="person">Dr. Schmidt</rs> has received consulting fees, speaking fees, and/or honoraria from <rs type="funder">Berlin-Chemie</rs>, <rs type="funder">Medac</rs>, <rs type="funder">Pfizer</rs>, <rs type="funder">AbbVie</rs>, <rs type="funder">Roche</rs>, <rs type="funder">Mundipharma</rs>, <rs type="institution">UCB</rs>, and <rs type="funder">MSD</rs>, and research funding from <rs type="funder">Mundipharma</rs>, <rs type="funder">Novartis</rs>, <rs type="affiliation">MJD Pharmaceutical, Actelion, General Electric, Esadie</rs>, and <rs type="person">Savient. Dr. Spiera</rs> has received research funding from <rs type="funder">Roche/Genentech</rs>. <rs type="person">Dr. Matteson</rs> has received research funding from <rs type="funder">Ardea</rs>, <rs type="funder">Sanofi</rs>, <rs type="funder">Centocor/Janssen</rs>, <rs type="funder">Celgene</rs>, <rs type="funder">Amgen</rs>, <rs type="funder">Roche</rs>, <rs type="funder">Genentech</rs>, <rs type="funder">Mesoblast</rs>, <rs type="funder">Novartis</rs>, <rs type="funder">Pfizer</rs>, and <rs type="institution">UCB Pharma</rs>. <rs type="person">Dr. Dasgupta</rs> has received consulting fees, speaking fees, and/or honoraria from <rs type="funder">Merck</rs> and research funding from <rs type="funder">Roche</rs>, <rs type="person">Mundipharma</rs>, and <rs type="funder">Servier</rs>.</p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>adverse events is usually lower than for efficacy data. This necessitated the use of relevant external evidence to strengthen this aspect of our recommendations.</p><p>These recommendations should support clinicians to achieve the best patient outcomes. Further research on existing drugs is necessary to offer additional, evidence-based treatment options to our patients. We anticipate an update of these recommendations 3 years after their publication; however, an earlier revision may be necessary if new data emerge that would modify the current recommendations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENT</head><p>We thank Catherine Wardle from Southend library for her assistance retrieving full text articles.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p>All authors contributed to conception and design of the study, acquisition and/or interpretation of data, drafting the article or revising it critically for important intellectual content, and approved the final version of the manuscript. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hutchings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hollywood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Lamping</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Pease</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chakravarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Silverman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="803" to="809" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dejaco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Duftner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Matteson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schirmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aging Health</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="633" to="645" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maradit</forename><surname>Kremers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Schirmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Salvarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="943" to="954" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maradit-Kremers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schirmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="484" to="492" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Population-based assessment of adverse events associated with long-term glucocorticoid use</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Westfall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Bijlsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>George</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="420" to="425" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The epidemiology of glucocorticoid-associated adverse events</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Mcdonough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Saag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="131" to="137" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica: a 10-year epidemiologic and clinical study</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Hunder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Ilstrup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Kurland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="672" to="680" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Long-term follow-up of polymyalgia rheumatica: evidence for synovitis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Healey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="322" to="328" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">An evaluation of criteria for polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Bird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Esselinckx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Mowat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Wood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="434" to="439" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Prognosis and management of polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Hazleman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Hamrin</surname></persName>
		</author>
		<author>
			<persName><surname>Polymyalgia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Med Scand Suppl</title>
		<imprint>
			<biblScope unit="volume">533</biblScope>
			<biblScope unit="page" from="1" to="131" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tugwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Knottnerus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="380" to="382" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">for the GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 3 of 3. The GRADE approach to developing recommendations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Brozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Compalati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kreis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Terracciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fiocchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="588" to="595" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Brozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jaeschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bossuyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Glasziou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1109" to="1116" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>for the GRADE Working Group</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Brozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Akl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Alonso-Coello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jaeschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="669" to="677" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>for the GRADE Working Group</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 EULAR-ACR recommendations for the management of polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dejaco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hutchings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Camellino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mackie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>In press</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 3. Rating the quality of evidence</title>
		<author>
			<persName><forename type="first">H</forename><surname>Balshem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Helfand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brozek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="401" to="406" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<ptr target="http://www.gradeworkinggroup.org/index.htm" />
		<title level="m">GRADE homepage</title>
		<imprint/>
		<respStmt>
			<orgName>Grade Working Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Evaluation of the quality of prognosis studies in systematic reviews</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hayden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bombardier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="427" to="437" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaujoux-Viala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="964" to="975" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>published erratum appears in Ann Rheum Dis 2011;70:1519</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="492" to="509" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gossec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaujoux-Viala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Marzo-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="4" to="12" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Dolan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Panayi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fernandes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebocontrolled trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Caporali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ferraccioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gerli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Klersy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="493" to="500" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Van Der Veen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Dinant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Booma-Frankfort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Van Albada-Kuipers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Bijlsma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="218" to="223" />
			<date type="published" when="1996">1996. 1996</date>
		</imprint>
	</monogr>
	<note>published erratum appears in Ann Rheum Dis</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Ferraccioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Salaffi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Vita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Casatta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="624" to="628" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>2578 DEJACO ET AL</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Efficacy of methotrexate in patients with polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Nazarinia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moghimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Toussi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Koomesh</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="265" to="270" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Borg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Barraclough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bourke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fulcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="186" to="190" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">NHG-Standaard Polymyalgia rheumatica en arteriitis temporalis</title>
		<author>
			<persName><surname>Nhg</surname></persName>
		</author>
		<ptr target="https://www.nhg.org/standaarden/volledig/nhg-standaard-polymyalgia-rheumatica-en-arteriitis-temporalis" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica und Riesenzellarteriitis (Arteriitis temporalis)</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gromnica</forename><surname>Ihle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Rationelle Diagnostik und Therapie in der Inneren Medizin: Leitlinien-basierte Empfehlungen f€ ur die Praxis</title>
		<editor>
			<persName><forename type="first">O</forename><surname>Busse</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><surname>Fleig</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><surname>Mayet</surname></persName>
		</editor>
		<imprint>
			<publisher>Elsevier</publisher>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months</title>
		<author>
			<persName><forename type="first">V</forename><surname>Kyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Hazleman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="658" to="661" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases</title>
		<author>
			<persName><forename type="first">N</forename><surname>Duru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Van Der Goes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1905" to="1913" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Grossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Ranganath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Deal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Caplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1515" to="1526" />
			<date type="published" when="2010">2012. 2010</date>
		</imprint>
	</monogr>
	<note>Care Res (Hoboken)</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Van Der Goes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Blom-Bakkers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1913" to="1919" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Hoes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Boumpas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Caeyers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1560" to="1567" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Dolan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moniz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mackintosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Todd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="2022" to="2029" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Long term treatment of polymyalgia rheumatica with deflazacort</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moggiana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Montecucco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Caporali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Accardo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="331" to="333" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Is the course of steroid-treated polymyalgia rheumatica more severe in women?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Parodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Caporali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Montecucco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1069</biblScope>
			<biblScope unit="page" from="315" to="321" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica. Duration of therapy and long-term outcome</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Ayoub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Franklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Torretti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="309" to="315" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Suppression of 17hydroxycorticosteroids in plasma and urine by single and divided doses of triamcinolone</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Grant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Forsham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Diraimondo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page">1115218</biblScope>
			<date type="published" when="1965">1965</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Rheumatoid arthritis: circadian rhythms in disease activity, signs and symptoms, and rationale for chronotherapy with corticosteroids and other medications</title>
		<author>
			<persName><forename type="first">E</forename><surname>Haus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sackett-Lundeen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Smolensky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bull NYU Hosp Jt Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">Suppl 1</biblScope>
			<biblScope unit="page" from="3" to="10" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Circadian ACTH-adrenal rhythm in man</title>
		<author>
			<persName><forename type="first">A</forename><surname>Angeli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chronobiologia</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="253" to="270" />
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Diurnal variation in suppression of adrenal function by glucocorticoids</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Nugent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Tyler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="343" to="349" />
			<date type="published" when="1965">1965</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Some clinical implications of the spontaneous diurnal variation in adrenal cortical secretory activity</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Raimondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Forsham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="321" to="323" />
			<date type="published" when="1956">1956</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Pharmacophysiologic principles in the use of corticoids and adrenocorticotropin</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Diraimondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Forsham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="5" to="24" />
			<date type="published" when="1958">1958</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Pituitary-adrenocortical reserve during corticosteroid therapy: a report on the methopyrapone test in ten patients taking long-continued small doses</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Deandrade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="261" to="262" />
			<date type="published" when="1964">1964</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome</title>
		<author>
			<persName><forename type="first">K</forename><surname>Barraclough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Liddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Du Toit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Foy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Fam Pract</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="328" to="333" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Relapse in a population based cohort of patients with polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">Maradit</forename><surname>Kremers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Reinalda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Crowson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Zinsmeister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Hunder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="65" to="73" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity</title>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boiardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ranzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Olivieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="303" to="308" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Cantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Olivieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Macchioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ranzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Niccoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="17" to="24" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Y</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kwok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatol Int</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1475" to="1480" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients</title>
		<author>
			<persName><forename type="first">G</forename><surname>Myklebust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Gran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="260" to="267" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate: a more benign syndrome</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gonzalez-Gay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rodriguez-Valverde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fernandez-Sueiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Armona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Figueroa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="317" to="320" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Macchioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Olivieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Niccoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Padula</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1221" to="1226" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ramiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaujoux-Viala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Nam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Buch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gossec</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="529" to="535" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Clinical observation on effect of modified Yanghe Decoction combined with glycocorticoid for treatment of polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Z</forename><surname>Fu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zhongguo Zhong Xi Yi Jie He Za Zhi</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="894" to="897" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Clinical observation about 18 cases of polymyalgia rheumatica by using Biqi capsule</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">China J Tradit Chinese Med Pharm</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="596" to="598" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Treatment of polymyalgia rheumatica: a systematic review</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hernandez-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Cid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Soto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Espigol-Frigole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bosch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="1839" to="1850" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Diamantopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hetland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Myklebust</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">120638</biblScope>
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series</title>
		<author>
			<persName><forename type="first">T</forename><surname>Adizie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Christidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dharmapaliah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Borg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Pract</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="906" to="909" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Effective control of polymyalgia rheumatica with tocilizumab</title>
		<author>
			<persName><forename type="first">Al</forename><surname>Rashidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hegazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">O</forename><surname>Mohammad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Varghese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="400" to="401" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature</title>
		<author>
			<persName><forename type="first">P</forename><surname>Macchioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boiardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Catanoso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pulsatelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pipitone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Meliconi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="113" to="118" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hagihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kawase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kishimoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1075" to="1076" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Azathioprine in giant cell arteritis/ polymyalgia rheumatica: a double-blind study</title>
		<author>
			<persName><forename type="first">De</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hazleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="136" to="138" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">and members of the International Work Group for PMR and GCA. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dejaco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Duftner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cimmino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dasgupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Crowson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="447" to="453" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aletaha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Bijlsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Boumpas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Burmester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="631" to="637" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>published erratum appears in Ann Rheum Dis 2011;70:1519</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gonz Alez-Gay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garc Ia-Porr Ua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Azguez-Caruncho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dababneh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hajeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ollier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1326" to="1332" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica. Long term treatment with steroids</title>
		<author>
			<persName><forename type="first">S</forename><surname>Paulsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ugeskr Laeger</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="944" to="945" />
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Acute-phase reactants and the risk of relapse/ recurrence in polymyalgia rheumatica: a prospective followup study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Salvarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Niccoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Macchioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Consonni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bajocchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="33" to="38" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">lnterleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Caplanne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Parc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Alexandre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="403" to="404" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Report of 6 cases with polymyalgia rheumatica and a review of the literature</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kanemaru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nagura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ooyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tomonaga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nihon Ronen Igakkai Zasshi</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="469" to="476" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
	<note>In Japanese</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Long-term outcome for patients with polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">S</forename><surname>Nagaoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ohno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ohno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rinshou Ryumachi</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="348" to="352" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>In Japanese</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Larrosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gratacos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page">1815216</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Proven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Gabriel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'fallon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Hunder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1333" to="1337" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tokuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Oshiawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Utsunomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kobayashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="148" to="153" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Peripheral musculoskeletal manifestations in polymyalgia rheumatica</title>
		<author>
			<persName><forename type="first">F</forename><surname>Ceccato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Roverano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Papasidero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barrionuevo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">L</forename><surname>Rillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Paira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="167" to="171" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Mackie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Hensor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Haugeberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bhakta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Pease</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="716" to="722" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Polymyalgia rheumatica with a low erythrocyte sedimentation rate: comparison of 10 cases with 10 cases with high erythrocyte sedimentation rate</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kanik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Bridgeford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Germain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Espinosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lowenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Valeriano-Marcet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="319" to="323" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
